Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
NYSE MKT:CANF
Can-Fite BioPharma (CANF) Stock Price & Analysis
458 Followers
CANF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.66 - $3.33
Previous Close$1.96
Volume10.46K
Average Volume (3M)20.99K
Market Cap
$10.27M
Enterprise Value$1.39M
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)-1.1
Beta1.05
Next Earnings
May 30, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding4,532,791
10 Day Avg. Volume20,499
30 Day Avg. Volume20,990
Standard Deviation0.20
R-Squared0.16
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.51
Price to Sales (P/S)11.96
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$18.00Price Target Upside813.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Can-Fite BioPharma News
PremiumCompany Announcements
Can-Fite’s Namodenoson Shows Promise for Liver Cancer
PremiumCompany Announcements
Can-Fite Advances MASH Treatment into Phase IIb
PremiumCompany Announcements
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
PremiumCompany Announcements
Can-Fite BioPharma Reports Reduced Losses in 2023
Ownership Overview
0.00%
Insiders
0.00%
Mutual Funds
3.50% Other Institutional Investors
96.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $1.66 and its highest was $3.33 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Currently, no data Available
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is May 30, 2024 which is in 41 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Mar 28, 2024. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.145.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -$0.4.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 4,990,428 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
---
Can-Fite BioPharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (813.71% Upside)
$18.00 (813.71% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.88%
12-Months-Change
Fundamentals
Return on Equity
-142.49%
Trailing 12-Months
Asset Growth
7.61%
Trailing 12-Months
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.
---
CANF Stock 12 Months Forecast
Average Price Target
$18.00
▲(813.71% Upside)
Technical Analysis
Best Analysts Covering CANF
1 Year
1 Year Success Rate
6/24 ratings generated profit
1 Year Average Return
-24.10%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -24.10% per trade.
---